Skip to main content
. 2007 Mar 16;64(3):304–316. doi: 10.1111/j.1365-2125.2007.02870.x

Figure 1.

Figure 1

Metabolic bone marker (CTX-S and CTX-U) variations during 4 weeks of CHF 4227 administration, expressed as a % of baseline values (mean ± SEM). *Statistically significant difference between CHF 4227 and placebo after 28 days of treatment, P < 0.05, Dunnett's test. 5 mg (▪), 10 mg (□), 25 mg (▴), 50 mg (▵), 100 mg (•), Placebo (○)